News for TBPMF Stock

Tetra Bio-Pharma Announces Listing to OTCPink Market REDUVO™ Marketing Approval on the Right Path Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003 Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean Tetra and Prepaire Jointly Apply to BARDA for Funding Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting Tetra Bio-Pharma Appoints Chief Financial Officer Tetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBD Tetra Bio-Pharma Announces Closing of First Tranche with Cannvalate Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology Tetra Bio-Pharma and Cannvalate Enter Into Partnership Tetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDA Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD Tetra Bio-Pharma Signs License Agreement with Thorne for a Prebiotic Dietary Supplement Tetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement Québec Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™ Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™ REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc. Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™ Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue Tetra Bio-Pharma Engages Christine Caron as Patient Partner Tetra Bio-Pharma Accelerates REBORN1© Trial Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003 Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients Tetra Bio-Pharma Receives Second Compliant Rating on Inspection from Health Canada Health Canada Provides Positive Feedback on Tetra Bio-Pharma’s Application for ARDS-003 to be Studied in COVID-19 Patients at Risk of Developing Acute Respiratory Distress Syndrome Tetra Bio-Pharma Initiates Additional Studies on Leading Drug Candidate ARDS-003 Tetra Bio-Pharma Adds Two Board Members and Appoints New COO Tetra Bio-Pharma Appoints Chief Financial Officer Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy Tetra Bio-Pharma Announces Plenitude Clinical Trial is Initiated Tetra Bio-Pharma Announces Data on its CBD Metabolite Study in Humans Tetra Bio-Pharma Engages Dalton Pharma for GMP Manufacturing of ARDS-003 Tetra Bio-Pharma and Mondias Enter Into Final Agreement For The Purchase Of Lumiera Health Innovation Inc. Tetra Bio-Pharma Receives Compliant Rating on Inspection from Health Canada Tetra Bio-Pharma Provides Status of Its New Drug Submission Application in Canada Correction To Tetra Bio-Pharma News Release Dated February 25th Tetra Bio-Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios Tetra Bio-Pharma Provides Update on Market Potential for QIXLEEF(TM) Tetra Bio-Pharma Provides Update on Recent Milestones Tetra Bio-Pharma Provides Update on Market Potential of ARDS-003 Tetra Bio Pharma Announces Divestiture of Lumiera Health Innovation Inc. Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19 Tetra Bio-Pharma Acquires Exclusive Global Technology Rights to a Mucoadhesive Delivery Technology Called Adversa(R) for its PPP-002 (dronabinol) drug candidate from IntelGenx Tetra Bio-Pharma Announces Positive Results in Animal Studies for Treatment of Hyperinflammatory Lung Injury Tetra Bio-Pharma Unveils its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio Tetra Bio-Pharma to Present at Alpha Bronze Virtual Town Hall Tetra Bio-Pharma (TBP) Acquires Dronabinol Soft Gel Capsules Exclusive Canadian Distribution Rights to Establish a Strong Commercial Presence in Canada and Accelerate its Profitability